We also developed a potent inhibitor of CYP2E1, Q11, as an effective glioma anti‐inflammatory agent for the treatment of GBM, findings provide a perspective on anti‐inflammatory GBM therapy and offer a new potential treatment strategy for GBM. This evidence concerns the gene CYP2E1 and central nervous system cancer.